ferent than for an initial diuretic or beta-blocker. In view of the similar (and not better) efficacy for a typically more expensive calcium antagonist, compared to a generally less expensive diuretic or beta-blocker in preventing most cardiovascular events, it is likely that the current large disparity in acquisition costs would support a public policy recommendation for an initial diuretic (or possibly a beta-blocker) as the more cost-effective initial choice. Treatment of hypertension over the past 3 decades using predominantly diuretic and beta-blocker drug regimens has been promoted as a factor in the reduction of cardiovascular disease related (CVD) and stroke-related mortality. Concurrent long-term measurement of end-stage renal disease (ESRD) morbidity in the US shows an increasing incident population for both hypertensive nephrosclerosis (HT-NS) and all-cause ESRD.
Treatment of hypertension over the past 3 decades using predominantly diuretic and beta-blocker drug regimens has been promoted as a factor in the reduction of cardiovascular disease related (CVD) and stroke-related mortality. Concurrent long-term measurement of end-stage renal disease (ESRD) morbidity in the US shows an increasing incident population for both hypertensive nephrosclerosis (HT-NS) and all-cause ESRD.
Utilizing the technique of data fusion, where concurrent observations of the same total population using different measurement tools are merged for analysis, we have evaluated available national databases for CVD mortality, stroke mortality, HT-NS incidence and ESRD incidence and have compared those data with a commercial database (IMS Health©) reflecting antihypertensive medication supply to US distributors for the period 1990 to 2001. The annual percentage change in manufacturer supply for diuretics was accepted to reflect the annual percent change in drug consumption by the US population at large. This premise permits analysis of annual variations in population-wide disease behavior concurrent with annual changes in population-wide drug category use.
Annual changes in prescription diuretic supply were observed to have the same pattern of fluctuations as the annual variability in ESRD incidence time-lagged two years later. Analysis of the relationship shows a significant (pϭ0.0001) direct curvilinear relationship (rϭ0.99795) existing between these variables over time. This relationship allows for the development of a simple linear model that relates annual percentage changes in diuretic supply and annual percentage changes in ESRD incidence two years later (Yϭ0.7X ϩ 1.16); (rϭ0.754, r 2 ϭ0.568, pϭ0.03).
The data from 1990 to 2001 show that changes in US diuretic supply and consumption were directly associated with changes in ESRD incidence in the US two years later. A hypothesis can be proposed that ESRD incidence rates might attenuate if diuretic use is deliberately minimized in the United States as much as possible.
Since the absolute number of new diuretic prescriptions in the US continues to rise annually, as does the population of incident ESRD patients, we propose that a prospective RCT trial would be justified to conclusively show the nephrotoxic causality of prolonged diuretic exposure within the population. influx and subsequent apoptosis in such cells. Both primary (collected at operation) and commercially available human colon cancer cell lines were used. The cells were incubated with three different CCB (verapamil, diltiazem or nifedipine) and one CCA (BayK 8644) at clinically relevant concentrations. RNA was determined by reversetranscription polymerase chain reaction (RT-PCR SuperScript one-Step). Intracellular Ca 2ϩ levels were measured by fluorometry (Fluo-4-AM). Apoptosis was quantified by flow cytometry (Annexin V binding). Cells from both lines expressed vascular (L-type) Ca 2ϩ channel mRNA but neither N-nor P-type channel mRNA. The L-type Ca 2ϩ channels were composed of a1D and b3-subunits. The selective L-type CCA BayK 8644 markedly increased Ca 2ϩ influx and apoptosis in the cells, and CCB pretreatment abolished BayK 8644-induced Ca 2ϩ influx and apoptosis. Accordingly, while there is no evidence that CCB induce transformation of normal cells to cancer cells, these drugs may promote growth of pre-existing cancer cells in humans. As this would become clinically relevant only in subjects who already harbor a critical mass of cancer cells, the negative results in clinical trials and the conflicting results of epidemiological studies are not surprising. Until studies have been conducted in appropriate patient groups to substantiate or refute the notion that CCB treatment poses a real cancer threat, it seems prudent to minimize the use of CCB in hypertensive patients.
